Apply to trial NCT06035744

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 1Drug trial

CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors

CLN-617-001 is a Phase 1, open-label, dose escalation, dose optimization and dose expansion study of CLN-617 alone and in combination with Pembrolizumab in patients with advanced solid tumors

How this works

  1. Answer a few questions

    About 5 to 10 minutes. Skip-friendly where possible.

  2. We forward your profile to the study team

    They see only the answers needed to decide if you can be screened.

  3. The team reaches out to schedule screening

    Usually within a few business days, via the contact you give.

By clicking Start, you agree to our terms of service.